INITIAL RESULTS OF THE RE-VERSE AD TRIAL: IDARUCIZUMAB REVERSES THE ANTICOAGULANT EFFECTS OF DABIGATRAN IN PATIENTS IN AN EMERGENCY SETTING OF MAJOR BLEEDING, URGENT SURGERY OR INTERVENTIONS
Charles V. Pollack(Hospital of the University of Pennsylvania), CW Kam(Boehringer Ingelheim (Germany)), Stephan Glund(Boehringer Ingelheim (Germany)), Thorsten Steiner(Heidelberg University), James Gagg(Musgrove Park Hospital), Jerrold H. Levy(Duke University), Peter Verhamme(KU Leuven), Frank W. Selke(Brown University), Robert Dubiel(Boehringer Ingelheim (Germany)), Pieter W. Kamphuisen(University Medical Center Groningen), Elaine M. Hylek(Boston University), B Wang(Boehringer Ingelheim (United States)), Jeffrey I. Weitz(McMaster University Medical Centre), John W. Eikelboom(Population Health Research Institute), Richard A. Bernstein(Northwestern University), Paul Reilly(Boehringer Ingelheim (United States)), Joachim Stangier(University of Bonn), J. Kreuzer(Boehringer Ingelheim (United States)), Menno V. Huisman(Leiden University Medical Center)
Cited by 7
Related Papers
Dabigatran versus Warfarin in Patients with Atrial Fibrillation
|New England Journal of Medicine|2009|11.2k
Prevalence of Diagnosed Atrial Fibrillation in Adults
|JAMA|2001|6.2k
Edoxaban versus Warfarin in Patients with Atrial Fibrillation
|New England Journal of Medicine|2013|5.2k
COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up
|Journal of the American College of Cardiology|2020|2.9k